Androgen Deprivation Therapy: What Happens When Testosterone Disappears

Most men are introduced to androgen deprivation therapy, commonly called ADT, as if it is an obvious and necessary step in prostate cancer treatment. The recommendation is often presented in simple terms. Lower testosterone, starve the cancer, slow progression, and improve outcomes. On the surface, that logic sounds straightforward. If prostate cancer cells use testosterone to grow, then eliminating testosterone must help control the disease.

That is conventional thinking. The problem is that this conversation is often dangerously incomplete. What many men are not told before starting ADT is what this treatment actually does to the rest of the body. Testosterone is rarely discussed as anything more than fuel for prostate cancer, as though its primary function is to stimulate disease. That is a profound oversimplification. Testosterone plays a central role in nearly every system that matters to male health. It affects muscle mass, bone density, metabolic health, cardiovascular function, cognition, mood, energy, sexual function, and resilience. When testosterone is suppressed to near-zero levels, every one of those systems responds.

The side effects of ADT are not rare or unusual, and they should not be framed as surprising complications affecting only a small percentage of men. They are predictable biological consequences of removing testosterone from the male body. When testosterone is aggressively suppressed, the effects extend far beyond the prostate. Fatigue becomes common, muscle mass declines, strength fades, and weight often increases, particularly through the accumulation of visceral fat. Bone density frequently worsens, insulin resistance rises, and cardiovascular risk increases over time. Sexual function is often significantly impaired or lost entirely, while mood changes and declining cognitive clarity become increasingly common.

Research published in JCO Oncology Practice and multiple oncology studies has consistently shown that androgen deprivation therapy significantly affects metabolic health, cardiovascular risk, bone density, and overall quality of life. A large review published in European Urology also demonstrated strong associations between ADT and increased risk of fractures, diabetes, and cardiovascular complications.

Before we even discuss whether ADT improves outcomes in a given situation, we need to acknowledge a fundamental truth: this treatment carries profound biological costs, and those costs must be weighed honestly.

This is where I believe modern medicine often gets the conversation wrong. Too much emphasis is placed on what ADT does to PSA, and far too little emphasis is placed on what ADT does to the man.

What ADT Does and What It Does Not Do

One of the biggest misconceptions in prostate cancer care is the belief that lowering PSA automatically means health is improving. This assumption drives an enormous amount of decision-making, particularly when men are placed on androgen deprivation therapy. The logic appears simple. If PSA goes down, treatment must be working. If treatment is working, the patient must be doing better. On the surface, that sounds reasonable. The problem is that the biology is far more complicated.

ADT reliably lowers PSA, which is one of the primary reasons it is so widely used in metastatic prostate cancer. When PSA falls, both physicians and patients often feel reassured because the improving number creates the appearance of progress and control. But this is exactly where men need to be careful.

PSA is a biomarker. It is not cancer. It is not a diagnosis, a direct measure of total disease burden, or a complete measure of health. In men receiving hormone suppression, PSA often falls because testosterone has been aggressively lowered and hormonal signaling has been suppressed. That does not automatically mean the broader picture has meaningfully improved.

I have seen many men told they are responding well because PSA looks better, while the rest of the body tells a very different story. Muscle mass declines. Strength fades. Bone density drops. Fatigue worsens. Metabolic health deteriorates. Cognitive clarity declines. Cardiovascular risk rises. On paper, treatment appears successful because the numbers improved. But when you look at the man sitting in front of you, the picture is often much more complicated.

That should force every man to ask a much harder question. What exactly are we calling success?

If PSA falls but strength disappears, is that success? If the numbers improve while energy, resilience, and quality of life steadily decline, what exactly has been gained?

These are uncomfortable questions, but they are necessary because modern prostate cancer care often places too much emphasis on surrogate markers and not enough emphasis on meaningful outcomes. Lowering PSA is not the same as improving health. Lowering PSA is not the same as preserving vitality. And lowering PSA is not always the same as meaningfully extending life in a way that justifies the biological cost of treatment.

The goal should never be reduced to chasing numbers alone. The goal should be preserving meaningful life for as long as possible. That means looking beyond PSA and asking harder questions about strength, resilience, vitality, independence, and quality of life. Those are the outcomes that matter most, and they should remain central in every treatment decision.

 The Clock Problem With ADT

Another major issue with androgen deprivation therapy is something many men are never clearly told before treatment begins: ADT is not a permanent solution. This is one of the most important realities in prostate cancer care, yet it is often not discussed with the level of honesty it deserves.

Prostate cancer biology is remarkably dynamic. Cancer cells are not static. They adapt, evolve, and respond to pressure over time. When prostate cancer is exposed to a low-testosterone environment for long enough, cancer cells begin developing survival mechanisms that allow them to bypass the very treatment designed to suppress them. They may amplify androgen receptors, activate alternate signaling pathways, or become increasingly efficient at growing despite minimal hormonal stimulation. Over time, many tumors learn how to survive and progress even in a near-castrate environment.

This is what leads to castration-resistant prostate cancer, one of the most difficult stages of prostate cancer to manage. At that point, the disease is no longer responding predictably to testosterone suppression, and treatment options often become more complex, more aggressive, and frequently more toxic. That reality should fundamentally change how men think about timing.

One of the biggest misconceptions is the belief that starting ADT earlier automatically improves outcomes by getting ahead of the disease. In some cases that may be true, particularly in men with symptomatic or aggressive metastatic disease. But in many other situations, starting ADT earlier does not eliminate the problem of resistance. It simply starts the clock sooner. The earlier hormone suppression begins, the earlier cancer cells are exposed to intense selective pressure, and the longer they have to adapt.

Research in major oncology literature has repeatedly shown that progression to castration-resistant disease remains one of the central limitations of long-term hormone suppression strategies. This is one of the unavoidable biological realities of ADT. The treatment can suppress disease for a period of time, but for many men it does not stop the evolutionary pressure driving cancer adaptation.

If ADT carries substantial biological costs, including muscle loss, bone loss, metabolic dysfunction, cardiovascular risk, cognitive decline, and loss of vitality, and if resistance eventually develops in many patients regardless, then the timing of when hormone suppression begins becomes critically important. 

The real issue is not simply whether ADT works in the short term. The real question is when hormone suppression provides enough meaningful benefit to justify both the biological cost and the reality that resistance may eventually develop. That is a much more complicated conversation than most men are led to believe, and it deserves far more thoughtful discussion before treatment begins.

Intermittent vs Continuous ADT

Conventional treatment often defaults to continuous ADT, where testosterone remains suppressed indefinitely. The logic appears straightforward. Keep testosterone low continuously, keep constant pressure on the cancer, and reduce the opportunity for disease progression. This sounds like the most aggressive and therefore the most effective strategy. The problem is that more aggressive does not always mean better, particularly when the biological costs of treatment are substantial.

This is where the evidence becomes much more interesting than many men realize. Multiple studies comparing intermittent versus continuous ADT have shown that intermittent treatment can provide similar survival outcomes in appropriately selected patients while reducing cumulative side effects and improving quality of life. The landmark NCIC PR-7 trial published in The New England Journal of Medicine found that intermittent androgen deprivation was not inferior to continuous therapy in men with rising PSA after radiotherapy. Men receiving intermittent therapy also experienced meaningful improvements in quality-of-life measures, including sexual function, fatigue, and overall well-being during off-treatment periods.

If similar survival can sometimes be achieved while reducing the cumulative burden of hormone suppression, why is continuous ADT so often treated as the automatic default?

The answer is often rooted in clinical habit rather than individualized strategy. Continuous suppression feels safer because it appears more aggressive. But aggressive treatment is not always smarter treatment. Continuous testosterone suppression places relentless biological stress on the body, and the longer a man remains in a near-castrate state, the greater the cumulative burden on muscle mass, bone density, cardiovascular health, metabolic function, cognition, and overall vitality.

This is why treatment strategy matters so much. The question is not simply whether ADT may be used. The more important questions are how it should be used, when it should be used, and for how long. These decisions can significantly affect both short-term quality of life and long-term health outcomes.

For some men, intermittent therapy may offer a more balanced strategy by helping control disease while reducing long-term biological damage. That does not mean intermittent therapy is appropriate for every patient, but it does mean the decision deserves far more individualized consideration than many men currently receive.

Why Testosterone Preservation Matters More Than Most Men Realize

Testosterone is not the enemy many men have been led to believe. In prostate cancer care, testosterone is often discussed as though it is purely a fuel source for cancer and something that should be eliminated as quickly as possible. That framing is far too simplistic and ignores the much larger role testosterone plays in male physiology.

Testosterone is one of the foundational drivers of male vitality. It plays a major role in maintaining muscle mass, bone density, metabolic health, cardiovascular function, cognitive performance, motivation, energy, and sexual health. In many ways, it helps determine how strong, resilient, and functional a man remains over time.

When testosterone levels collapse, the consequences extend far beyond cancer management. Men often experience profound physical and psychological changes that affect daily life in meaningful ways. Muscle mass declines, strength fades, body fat increases, metabolic health worsens, and energy often drops significantly. Many men also notice worsening cognition, lower motivation, and major changes in sexual function.

This is why testosterone preservation deserves far more attention than it typically receives. The conversation should not be reduced to simply suppressing testosterone whenever prostate cancer enters the picture. The real question is when the benefits of hormone suppression clearly outweigh the biological cost.

When ADT Actually Makes Sense

None of this means androgen deprivation therapy never has a role in prostate cancer care. There are absolutely situations where hormone suppression provides meaningful clinical benefit. Men with symptomatic metastatic disease, significant bone pain, urinary obstruction, spinal cord compression risk, or aggressive high-volume progression may benefit substantially from carefully selected hormone suppression. In these settings, reducing tumor burden and slowing progression may relieve symptoms, preserve function, and in some cases improve survival.

The problem is not ADT itself. The problem is how reflexively it is often used in men who do not yet clearly need it or not being open to using Intermittent therapy.

Too many men are started on hormone suppression at the earliest sign of PSA progression without enough discussion about whether early intervention meaningfully improves long-term outcomes. A rising PSA creates anxiety for both physicians and patients, and that anxiety often drives treatment decisions more than thoughtful analysis.

Research from the TOAD trial and data from the CaPSURE registry raised important questions about whether immediate hormone suppression consistently improves survival in asymptomatic men with biochemical recurrence. That should encourage a much more thoughtful conversation, because not every rising PSA requires immediate hormonal intervention.

Before starting ADT, every man should understand why treatment is being recommended, what benefit is expected, and what tradeoffs come with that decision.

Final Thoughts

Before agreeing to androgen deprivation therapy, every man deserves clear answers to difficult questions. Is there strong evidence that starting ADT now will meaningfully improve survival in my specific case? What benefit am I realistically expecting, and what am I sacrificing in exchange?

Hormone suppression affects far more than prostate cancer alone. It can influence strength, energy, bone density, cardiovascular health, metabolic function, cognition, and overall quality of life. This is where men need to think carefully. The goal should never be treatment for the sake of treatment. The goal should be preserving meaningful life for as long as possible while making decisions that balance longevity with quality of life.

If you or someone you care about is being told to start ADT, slow down before making irreversible decisions. Ask harder questions. Demand clearer answers. Understand not only what treatment is expected to do to the cancer, but what it may do to the rest of your body.

That is how better decisions are made. That is how regret is avoided. That is what it means to fight cancer like a man.

If you want a deeper understanding of androgen deprivation therapy, treatment timing, and how to think strategically about prostate cancer care, watch Dr. Petteruti’s full discussion on this topic. You can also explore these concepts in greater depth in Fight Cancer Like a Man, where he breaks down the evidence, challenge conventional assumptions, and focus on what matters most: preserving both longevity and life worth living.

If you want personalized guidance on your prostate cancer journey, schedule a consultation with Dr. Stephen Petteruti to discuss your options and make sure you fully understand the path in front of you before making irreversible decisions.

About Dr. Stephen Petteruti

Dr. Stephen Petteruti is a physician focused on men’s health, hormone optimization, longevity, and prostate cancer care. His approach challenges conventional thinking by focusing on root causes, metabolic health, and long-term vitality. His goal is not simply helping patients live longer, but helping them preserve strength, energy, resilience, and quality of life as they age.

Learn more at https://www.drstephenpetteruti.com/ 

References

1. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359-2366.
2. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386-396.
3. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.
4. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63(4):742-745.
5. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164.
6. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(2 suppl 1):32-38.
7. Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825-836.

8. Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17(6):727-737.

9. Kawakami J, Cowan JE, Elkin EP, Latini DM, Duchane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106(8):1708-1714.